Skip to main content
Premium Trial:

Request an Annual Quote

John Hertig, Fabrice Egros, Eric Tomlinson, Pedro “Pete” Pizarro, Kenneth Wright, Diane Cook, Paul Hsu, Andy Hyltin, William Ringo Jr., Joseph Thomas, Evangelia Evdaimon, Rod Fuller, Casey Lobring

Former Enpath President/CEO Named Director of Biomedical Institute at Purdue U
John Hertig, former president and CEO of Enpath Medical in Minneapolis, has been named the inaugural executive director of the Alfred Mann Institute for Biomedical Development at Purdue University in West Lafayette, Ind. His duties include overseeing the institute's development and subsequent transfer of selected Purdue technologies in the biomedical field. Hertig also will be responsible for managing the institute and fostering relationships with potential commercial partners.
The institute was established in March 2007 through a $100 million endowment from the Alfred Mann Foundation for Biomedical Engineering, as part of a partnership with Purdue and the Purdue Research Foundation. The institute — the third to be created worldwide through the Mann Foundation — is designed to enable the commercialization of innovative biomedical technologies intended to improve human health.

UCB, Altea Therapeutics Presidents Elected Georgia Bio Co-Chairs for 2008
Fabrice Egros, US president of UCB, and Eric Tomlinson, president of Altea Therapeutics, have been elected co-chairs of Georgia Bio’s board of directors for 2008. Egros and Tomlinson succeed Russell Medford, president and CEO of AtheroGenics, who will remain on GaBio’s board and its executive committee as immediate past chair. Their duties will include presiding over GaBio, Georgia’s life sciences industry group, as it plans to host the 2009 Biotechnology Industry Organization International Convention, to be held in Atlanta May 17-20, 2009.
Tomlinson has served since 2002 as president and CEO of Altea Therapeutics, a developer of pharmaceutical products based on transdermal patches that deliver therapeutic levels of water-soluble small-molecule drugs, proteins, and carbohydrates. Tomlinson previously established and led the worldwide advanced drug delivery research program for Ciba-Geigy Pharmaceuticals (now Novartis), and served as CEO of GeneMedicine.
Egros has served since 2006 as president of the US subsidiary of UCB, a biopharmaceutical company headquartered in Brussels, Belgium. Previously he served as representative director and president of UCB Japan. Earlier he held positions with Parke-Davis/Warner Lambert in the US and with Sanofi-Aventis in Japan and the US.
Founded in 1989, GaBio is a private, nonprofit organization with 320 members.

Enterprise Florida Appoints Five Directors to New Florida Opportunity Fund
The Enterprise Florida board of directors has appointed five business leaders to serve as board members of the Florida Opportunity Fund, created by the 2007 Florida Capital Formation Act to generate early stage capital and technology commercialization in the Sunshine State:
  • Pedro “Pete” Pizarro, president, director and CEO of Telefonica USA, a Miami-based provider of communication and IT services.
  • Kenneth Wright, a partner in the Orlando law firm Baker Hostetler whose practice has included international and domestic securities and venture capital financing.
  • Diane Cook, vice president and treasurer of the University of Miami since 1991
  • Paul Hsu, a serial entrepreneur focused on high-tech business, and an inductee into the US Small Business Administration’s Hall of Fame.
  • Andy Hyltin, president of CNL Private Equity Corporation in Orlando.
Pizarro will serve as chairman, and Wright, as vice chairman. Current and future member terms will be staggered, beginning with Pizarro serving for three years; Wright and Cook, for two years; and Hsu and Hyltin, for a year.
Enterprise Florida is the Orlando-based public-private group that oversees Florida’s economic development effort.

Chairman of Three Companies Named to Board of Indiana’s BioCrossroads
William Ringo Jr. has been elected to the board of directors of BioCrossroads, Indiana’s life sciences industry group. Ringo serves as chairman of the board of directors for Hyperion, InterMune, and Portola Pharmaceuticals; and is also a member of the boards of Allos Therapeutics, Inspire Pharmaceuticals, and Alvine Pharmaceuticals.
Ringo retired from Eli Lilly and Company in 2001 after 28 years of service in a variety of key roles; his last position was president of Eli Lilly’s oncology and critical care products unit. Since 2001, Ringo has served in a variety of biotech board and leadership positions, including president and CEO of Abgenix (acquired by Amgen), and as interim president and CEO of InterMune.
Ringo is currently the CEO in residence at Warburg Pincus, a private equity firm, and the executive in residence at Sofinnova Ventures.

Cincinnati-Based Biotechnology Attorney Named a 2008 Leading Lawyer
Joseph Thomas, a lawyer in the Cincinnati office of the law firm Ulmer & Berne who specializes in biotechnology cases, has been named a 2008 Leading Lawyer by the magazine Cincy Business. Thomas was among winners deemed among the most prominent and powerful legal minds within the Greater Cincinnati area. Winners were nominated by colleagues outside their firms and chosen by a panel of their peers.

Thomas chairs the firm’s pharmaceutical industry practice within its life sciences group, and co-chairs the firm’s litigation department. He has represented clients in litigation involving fen/phen, antidepressant, ephedra, hormone replacement therapy, ADHD, and other treatments. Thomas’ experience includes toxic tort defense, drug and medical device litigation, products liability defense, class action and mass tort litigation involving drugs and medical devices.
He graduated from Washington State University with a BPharm degree in 1980, from the University of Cincinnati with a PharmD degree in 1982, and from Northern Kentucky University with a JD degree cum laude in 1988. From 1982 to 1988 he was chief of the inpatient pharmacy at Cincinnati VA Medical Center.

InfoStrength Quality Director Elected to a Third Term with NCCSQA
Evangelia Evdaimon has been elected to her third term as chair of the issues and methods committee for the North Carolina Chapter of the Society of Quality Assurance. The chapter serves North Carolina’s Research Triangle Park and Piedmont Triad regions, and has a membership of over 250 active quality professionals. Evdaimon is the director of quality at InfoStrength, a developer of software solutions for biotech, pharmaceutical and medical device companies.

Life Sciences Lawyer Named Shareholder in Phoenix Law Firm Fenimore Craig
Rod Fuller, an intellectual property and life sciences lawyer with Fenimore Craig, has been elected a shareholder in the Phoenix law firm. Fuller focuses on biotechnology, including genetic engineering, molecular biology, genomics, immunology and drug-delivery systems. He received his law degree from the J. Reuben Clark Law School at Brigham Young University in 2000.

Tech Policy Journal Editor Named New Associate in Law Firm’s Biotech Practice
Casey Lobring has been appointed an associate in the Del Mar, Calif., office of the law firm Foley & Lardner.  A member of the firm’s biotechnology and pharmaceutical practice group, Lobring’s practice will focus on areas that include preparing and prosecuting patent applications.
Lobring earned his law degree from the University of Illinois College of Law, where he was an associate editor of the Journal of Law, Technology & Policy and received the distinction of honors in legal research and writing.  He earned his doctorate in chemistry from Northern Illinois University and received his bachelor’s degree in chemistry and mathematics from McKendree College in Lebanon, Ill.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.